| Oct 25 |
Aclarion files to sell 20M shares of common stocks by selling shareholders
|
| Oct 10 |
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Sep 27 |
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
|
| Sep 13 |
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
|
| Sep 12 |
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
|
| Sep 11 |
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
|
| Sep 10 |
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
|
| Sep 6 |
Aclarion Added to PRISM Emerging Medical Devices Index
|
| Sep 5 |
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
|
| Aug 29 |
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
|
